Piao Y F, Okabe T, Zhang L J
Third Dept. of Internal Medicine, Faculty of Medicine, University of Tokyo.
Gan To Kagaku Ryoho. 1990 Feb;17(2):281-5.
Harringtonine was discovered as an anticancer agent in China. It has been shown to be effective against myeloid leukemia. In this report, we have demonstrated that harringtonine inhibited the growth of human myeloid leukemia cells in vitro at low concentrations. Together with the clinical data in which 28% of the patients could be induced into complete remission only by harringtonine, this agent may be used as a first choice of antileukemia agents in the treatment of myeloid leukemia. The mechanism of the antitumor action of harringtonine is considered to be an effect on protein synthesis and is characterized by breakdown of polysomes to monosomes. The mechanism of action appears to be different from those of the other antileukemia agents, such as cyclophosphamide, daunorubicin, vincristine, or cytosine arabinoside. Harringtonine could be added to the other anti-leukemia agents used routinely in treatment of leukemia, and the combination of harringtonine with the other agents is expected to improve the therapy of myeloid leukemia.
三尖杉酯碱是在中国被发现的一种抗癌药物。已证明它对髓细胞白血病有效。在本报告中，我们已证明三尖杉酯碱在低浓度下可体外抑制人髓细胞白血病细胞的生长。连同28%的患者仅用三尖杉酯碱就能诱导完全缓解的临床数据，该药物可作为治疗髓细胞白血病的抗白血病药物的首选。三尖杉酯碱的抗肿瘤作用机制被认为是对蛋白质合成的影响，其特征是多核糖体分解为单核糖体。其作用机制似乎与其他抗白血病药物不同，如环磷酰胺、柔红霉素、长春新碱或阿糖胞苷。三尖杉酯碱可添加到白血病治疗中常规使用的其他抗白血病药物中，预计三尖杉酯碱与其他药物联合使用可改善髓细胞白血病的治疗。
